Published in Behav Pharmacol on May 01, 2008
Novel RNAi-mediated approach to G protein-coupled receptor deorphanization: proof of principle and characterization of a planarian 5-HT receptor. PLoS One (2012) 0.80
5-HT(1A)-like receptor activation inhibits abstinence-induced methamphetamine withdrawal in planarians. Neurosci Lett (2010) 0.75
Planarian brain regeneration as a model system for developmental neurotoxicology. Regeneration (Oxf) (2016) 0.75
Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract (2010) 1.53
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol (2011) 1.22
Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2. Eur J Pharmacol (2007) 1.15
Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology (Berl) (2005) 1.13
The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations. Pharmacol Ther (2010) 1.07
Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther (2005) 1.06
Beta-lactam antibiotic decreases acquisition of and motivation to respond for cocaine, but not sweet food, in C57Bl/6 mice. Behav Pharmacol (2011) 1.06
Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology (Berl) (2008) 1.04
The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse. Drug Alcohol Depend (2009) 1.03
Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians. Pharmacol Biochem Behav (2009) 1.03
Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. Curr Med Res Opin (2013) 1.02
Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther (2003) 1.01
An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2). Pharmacol Biochem Behav (2007) 0.97
A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract (2012) 0.97
The beta-lactam antibiotic ceftriaxone inhibits physical dependence and abstinence-induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians. Eur J Pharmacol (2008) 0.97
Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology (2013) 0.97
Nicotine behavioral pharmacology: clues from planarians. Drug Alcohol Depend (2011) 0.95
Glutamate and aspartate measurements in individual planaria by rapid capillary electrophoresis. J Pharmacol Toxicol Methods (2010) 0.95
The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation. Pharmacol Biochem Behav (2008) 0.94
First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planarians. Behav Pharmacol (2010) 0.94
Transversus abdominis block: clinical uses, side effects, and future perspectives. Pain Pract (2013) 0.94
Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse. Psychopharmacology (Berl) (2009) 0.93
Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice. J Pharmacol Exp Ther (2008) 0.92
Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol (2009) 0.92
A nitric oxide synthase inhibitor (L-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in Planaria. Brain Res (2006) 0.91
Continuous multimechanistic postoperative analgesia: a rationale for transitioning from intravenous acetaminophen and opioids to oral formulations. Pain Pract (2011) 0.91
Effect of cannabinoid CB1 receptor antagonist SR141716A and CB1 receptor knockout on cue-induced reinstatement of Ensure and corn-oil seeking in mice. Neuropsychopharmacology (2007) 0.89
Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice. Psychopharmacology (Berl) (2011) 0.88
Sucrose produces withdrawal and dopamine-sensitive reinforcing effects in planarians. Physiol Behav (2013) 0.88
Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol (2014) 0.88
Opioid receptors and acetaminophen (paracetamol). Eur J Pharmacol (2004) 0.86
Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting. J Clin Anesth (2012) 0.86
Measurement of glutamate and aspartate in Planaria. J Pharmacol Toxicol Methods (2005) 0.85
On deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical data. Drug Alcohol Depend (2010) 0.85
Pain treatment in arthritis-related pain: beyond NSAIDs. Open Rheumatol J (2012) 0.85
Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay. J Pharmacol Exp Ther (2003) 0.84
Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity (Silver Spring) (2011) 0.82
Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol (2008) 0.82
Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. J Pain Res (2012) 0.82
A reverse-phase HPLC and fluorescence detection method for measurement of 5-hydroxytryptamine (serotonin) in Planaria. J Pharmacol Toxicol Methods (2004) 0.82
Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation. Eur J Pharmacol (2008) 0.81
Withdrawal-like behavior in planarians is dependent on drug exposure duration. Neurosci Lett (2008) 0.81
Sex and cannabinoid CB1 genotype differentiate palatable food and cocaine self-administration behaviors in mice. Behav Pharmacol (2009) 0.81
Cocaine and kappa-opioid withdrawal in Planaria blocked by D-, but not L-, glucose. Brain Res (2004) 0.81
Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats. Psychopharmacology (Berl) (2009) 0.80
Differential behavioral effect of the TRPM8/TRPA1 channel agonist icilin (AG-3-5). Eur J Pharmacol (2007) 0.80
Effects of early chemotherapeutic treatment on learning in adolescent mice: implications for cognitive impairment and remediation in childhood cancer survivors. Clin Cancer Res (2013) 0.80
Planarians in pharmacology: parthenolide is a specific behavioral antagonist of cocaine in the planarian Girardia tigrina. Int J Dev Biol (2012) 0.80
Agmatine: identification and inhibition of methamphetamine, kappa opioid, and cannabinoid withdrawal in planarians. Synapse (2008) 0.80
Tapentadol extended release for chronic pain patients. Adv Ther (2013) 0.79
Extended-release formulations of tramadol in the treatment of chronic pain. Expert Opin Pharmacother (2011) 0.79
Opioid antagonists for pain. Expert Opin Investig Drugs (2013) 0.79
Nociceptin attenuates methamphetamine abstinence-induced withdrawal-like behavior in planarians. Neuropeptides (2008) 0.79
Temperature-dependent enhancement of the antinociceptive effects of opioids in combination with gabapentin in mice. Eur J Pharmacol (2012) 0.79
Changes in aorta alpha1-adrenoceptor number and affinity during one year of streptozotocin-induced diabetes in rats. Pharmacology (2005) 0.78
Disruption of learning processes by chemotherapeutic agents in childhood survivors of acute lymphoblastic leukemia and preclinical models. J Cancer (2011) 0.78
In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism. Neurosci Lett (2012) 0.78
Preliminary observations of a novel topical oil with analgesic properties for treatment of acute and chronic pain syndromes. Pain Pract (2010) 0.78
Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity. Expert Opin Drug Saf (2014) 0.78
Isothermal titration calorimetric study of RNase-A kinetics (cCMP --> 3'-CMP) involving end-product inhibition. Pharm Res (2004) 0.77
Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: III. Retinoids. J Clin Pharm Ther (2002) 0.77
Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Behav Pharmacol (2015) 0.77
Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature. J Pain Res (2012) 0.77
Looking beyond the administered drug: metabolites of opioid analgesics. J Fam Pract (2008) 0.77
Pain and obesity in the older adult. Curr Pharm Des (2014) 0.76
Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse- deterrent formulations. Curr Pharm Des (2012) 0.76
Acetaminophen and metabolite: lack of effect on nitric oxide synthase (constitutive or inducible). Headache (2002) 0.76
Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assay. Amino Acids (2011) 0.76
Liquid chromatography-mass spectrometric analysis of buprenorphine and its N-dealkylated metabolite norbuprenorphine in rat brain tissue and plasma. J Pharmacol Toxicol Methods (2005) 0.76
Combining opioid and adrenergic mechanisms for chronic pain. Postgrad Med (2014) 0.76
An open-label pharmacokinetic study of oxymorphone extended release in the presence of naltrexone in the older adult. J Opioid Manag (2012) 0.75
Evaluation of a novel topical essential oxygen oil for the treatment of pain in acute tendinopathy and sprains. Muscles Ligaments Tendons J (2011) 0.75
Endothelin antagonists in CION injury model. Pain (2006) 0.75
Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine. Biomed Chromatogr (2013) 0.75
5-HT(1A)-like receptor activation inhibits abstinence-induced methamphetamine withdrawal in planarians. Neurosci Lett (2010) 0.75
LiCl attenuates M(1)AChR-mediated intrathecal pilocarpine-induced reciprocal hindlimb scratching in mice. Pharmacology (2002) 0.75
Cocaine synergism with α agonists in rat aorta: computational analysis reveals an action beyond reuptake inhibition. Drug Alcohol Depend (2012) 0.75
'Null method' determination of drug biophase concentration. Pharm Res (2011) 0.75
The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain. Adv Ther (2015) 0.75
Intranasal ketorolac as part of a multimodal approach to postoperative pain. Pain Pract (2014) 0.75
Toward the design of ribonuclease (RNase) inhibitors: ion effects on the thermodynamics of binding of 2'-CMP to RNase A. J Pharmacol Exp Ther (2002) 0.75
Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain. Expert Rev Neurother (2015) 0.75
Ethylene bis-imidazoles are highly potent and selective activators for isozymes VA and VII of carbonic anhydrase, with a potential nootropic effect. Chem Commun (Camb) (2014) 0.75
Is morphine medicine's biggest misnomer? Ann Pharmacother (2012) 0.75
Considerations on the use of oxymorphone in geriatric patients. Expert Opin Drug Saf (2009) 0.75